Artificial Intelligence and supercomputers have changed the drug discovery game by reducing the overall time and money required to identify, as well as develop into therapeutics elegant as new molecular entities. Drug development through traditional techniques is a labor intensive and hence costly process, Artificial Intelligence -supported ways happening at an incredible rate molecular modelling, virtual screening and predictive analytics used in conjunction with high-performance computing. Artificial Intelligence is able to determine binding of drugs to targets, improve molecular structures & repurpose existing drugs for new applications, especially for emerging infectious diseases such as COVID-19. In a fraction of seconds that supercomputers complete billions of calculations, molecular docking and high-throughput screening can be utilized to streamline efficacy, raking more bang for the science buck of drug discovery. Moreover, Artificial Intelligence High-Performance Computing collaboration is aimed at enhancing clinical trial speed by streamlining patient matching, predictable response to treatment and automated trial data analysis. Artificial Intelligence and supercomputers are cost effective, enhance precision in delivering improved outcomes which serves as critical tool in cutting edge biomed research, with a focus not limited to pharmaceutical innovations. This literature review is a compilation of current literature works to reflect the potential of Artificial Intelligence and supercomputing in revolutionizing drug discovery, clinical trials as well emanating vaccine not only for potential future requirements but also under tackled priorities but also address current challenges and opportunities relevant to this area.